Abbvie Inc. has prepared and tested new antibody-drug conjugates comprising an antibody targeting seizure protein 6 homolog (SEZ6) covalently linked to DNA topoisomerase I inhibitors through a linker.
Asgard Therapeutics AB has raised €30 million (US$32.8 million) in a series A round to advance a novel approach to cancer immunotherapy, in which it is proposed to reprogram cancer cells into functional antigen-presenting dendritic cells in vivo, activating a host immune response against the tumor.
Cytokinetics Inc. has disclosed fast skeletal muscle myosin inhibitors reported to be useful for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, spinal cord injury, limb girdle muscular dystrophy, stroke, tendinitis and tremor, among others.
Jawaharlal Nehru Centre for Advanced Scientific Research has divulged naphthalene monoimide compounds acting as modulators of liquid-liquid phase separation (LLPS) of tau protein reported to be useful for the treatment of traumatic encephalopathy, progressive supranuclear palsy, tauopathies, frontotemporal dementia and Alzheimer’s disease.
Hangzhou Highlightll Pharmaceutical Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammation, liver and metabolic disease, neuroinflammation, immunological, cardiovascular and renal disorders.
Jinyao Biotechnology (Tianjin) Co. Ltd. has synthesized glucocorticoid receptor (GR) agonists reported to be useful for the treatment of psoriasis, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, eczema, allergic rhinitis and Crohn’s disease.
Recent studies have identified HAVCR2, which encodes immune checkpoint molecule TIM-3 (T-cell immunoglobulin mucin receptor 3), as a risk gene for late-onset Alzheimer’s disease (AD).
RSS
